242 related articles for article (PubMed ID: 11523926)
1. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
[TBL] [Abstract][Full Text] [Related]
2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
4. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
5. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
Müller AM; Weichert A; Müller KM
Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
[TBL] [Abstract][Full Text] [Related]
8. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
10. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
11. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
Warhol MJ; Hickey WF; Corson JM
Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872
[TBL] [Abstract][Full Text] [Related]
12. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
[TBL] [Abstract][Full Text] [Related]
14. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
15. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
16. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
17. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
18. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
Jordon D; Jagirdar J; Kaneko M
Am J Pathol; 1989 Nov; 135(5):931-7. PubMed ID: 2817084
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
20. "Thick" cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.
Leong AS; Parkinson R; Milios J
Diagn Cytopathol; 1990; 6(1):9-13. PubMed ID: 2323301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]